chartexchange

UroGen Pharma Ltd (URGN) (Q3 2026) Earnings Call Highlights: Zysturi's 35% Sequential Surge and ...

GuruFocus | Nov 4, 2026 10:09 PM EST

UroGen Pharma Ltd (URGN) posted $68 million in Zysturi revenue, grew unique prescribers to 662, and expects positive cash flow in Q4 2026 despite Gelmito headwinds. Related Stocks: URGN ,

Read original article